|4.||Venous Thrombosis (Deep-Vein Thrombosis)
|1.||Palareti, Gualtiero: 44 articles (11/2015 - 01/2002)|
|2.||Eriksson, Bengt I: 40 articles (01/2015 - 01/2002)|
|3.||Turpie, Alexander G G: 40 articles (02/2014 - 01/2002)|
|4.||Ageno, Walter: 39 articles (12/2015 - 08/2002)|
|5.||Prandoni, Paolo: 38 articles (11/2015 - 03/2002)|
|6.||Prins, Martin H: 37 articles (01/2015 - 03/2002)|
|7.||Büller, Harry R: 35 articles (11/2015 - 03/2002)|
|8.||Agnelli, Giancarlo: 33 articles (09/2015 - 03/2002)|
|9.||Cushman, Mary: 32 articles (11/2015 - 04/2002)|
|10.||Wells, Philip S: 32 articles (08/2015 - 07/2002)|
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
09/01/1998 - "In conclusion, low-molecular-weight heparin is highly effective in preventing post-operative venous thromboembolism."
12/01/2001 - "This article reviews the developments that have occurred in the treatment of venous thromboembolism during the last decade, with emphasis on the establishment of low molecular weight heparin as a therapeutic agent of proven efficacy and examines the evidence that supports the movement from inpatient to outpatient hospital management of venous thromboembolism."
12/01/1996 - "Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism."
10/01/2008 - "The present study is the largest study to have examined the clinical efficacy of once daily LMWH for use in pregnant women at high risk of venous thromboembolism. "
01/01/2002 - "Analysis of pooled data for category I studies showed a non-significant reduction in the risk of recurrent venous thromboembolism favoring low-molecular-weight heparin treatment (OR 0.75; 95% CI [0.40, 1.39]). "
|2.||Heparin (Liquaemin)FDA LinkGeneric
12/01/2002 - "Low molecular weight heparins have improved pharmacokinetic and pharmacodynamic properties over unfractionated heparin that have resulted in greater efficacy and safety in the field of venous thromboembolism. "
01/01/2000 - "Low molecular weight heparins have improved pharmacokinetic and pharmacodynamic properties over unfractionated heparin that have resulted in greater efficacy and safety in the field of venous thromboembolism. "
01/01/1999 - "The SCD/GES combination and heparin are each effective in preventing venous thromboembolism in individuals' acute traumatic SCI. Effectiveness of heparin prophylaxis may be greatest during the first 14 days after injury, whereas benefit from SCD continues to 6 weeks after injury."
09/01/1998 - "Unfractionated heparin has withstood the test of time and has been shown to be safe and effective in preventing recurrent venous thromboembolism and death in numerous clinical trials. "
06/15/2001 - "Unfractionated heparin (UFH) is the traditional standard for the initial treatment of venous thromboembolism (VTE) but low molecular weight heparins (LMWHs) have been shown to be equally safe and effective in hemodynamically stable patients. "
|3.||Warfarin (Coumadin)FDA LinkGeneric
06/01/2010 - "Pharmacogenomic warfarin dosing has been suggested to produce more accurate dosing and an improved patient safety profile; however, very few models have been derived in patients with venous thromboembolism. "
08/14/2003 - "Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. "
01/01/2010 - "Dabigatran is as effective as Warfarin in the treatment of acute venous thromboembolism - the RE-COVER study."
12/10/2009 - "For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfarin, and does not require laboratory monitoring. "
07/01/2004 - "Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no."
|4.||Enoxaparin (Lovenox)FDA LinkGeneric
12/01/2013 - "Although higher dosing of enoxaparin led to improved anti-Xa levels, this did not equate to a statistical decrease in venous thromboembolism."
05/01/2004 - "In general surgery the efficacy of enoxaparin to prevent venous thromboembolism is similar to UFH but the tolerability is better. "
04/01/2013 - " and enoxaparin were both effective in preventing venous thromboembolism in Japanese patients undergoing elective TKA. "
11/01/2011 - "The Venous Thromboembolism Prevention Study has shown that enoxaparin prophylaxis is a safe and effective way of preventing postoperative venous thromboembolism. "
06/01/2013 - "Enoxaparin is effective and safe in surgical patients to prevent venous thromboembolism."
09/01/2009 - "Since it has been shown that most venous thromboembolism events occur following hospital discharge, these new anticoagulants may result in very significant reduction in the overall incidence of venous thromboembolism events."
02/01/2015 - "Objective diagnosis and treatment are important in optimizing clinical outcomes in patients with venous thromboembolism (VTE), and anticoagulants are the mainstay of treatment. "
11/01/2011 - "In the last decade, parenteral anticoagulants have proven to be effective in the prevention of venous thromboembolism (VTE) in patients admitted to hospitals. "
04/01/2013 - "After reports from observational studies suggesting an association between acutely ill medical patients and venous thromboembolism (VTE), interventional trials with anticoagulants drugs have demonstrated a significant reduction of VTE during and immediately after hospitalisation. "
06/01/2007 - "Clinical trials have repeatedly demonstrated superior efficacy over other anticoagulants as venous thromboembolism prophylaxis and several cost-effectiveness studies have demonstrated cost savings with this drug."
|6.||fondaparinux (Arixtra)FDA Link
01/01/2004 - "The further randomized, double-blind PENTHIFRA-PLUS trial showed that extending fondaparinux prophylaxis from one to four weeks after hip fracture surgery was well tolerated and, compared to one-week fondaparinux, dramatically reduced delayed venous thromboembolism events from 35.0% to 1.4% (p<0.001). "
01/01/2008 - "In a well designed trial (ARTEMIS) in acute medical patients aged > or = 60 years, fondaparinux was significantly more effective than placebo in terms of reducing the incidence of venous thromboembolism (VTE) up to day 15. "
07/01/2004 - "In patients undergoing elective hip replacement surgery, fondaparinux significantly reduced the frequency of venous thromboembolism (VTE). "
03/01/2004 - "Fondaparinux (Arixtra), a specific AT-dependent FXa inhibitor, is effective and safe in the prevention and treatment of venous thromboembolism, but some major hemorrhagic events may occur. "
11/01/2012 - "Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study."
09/01/2015 - "Venous thromboembolism can be safely and effectively treated by rivaroxaban, and does of 15 mg twice daily for 21 days followed by 20 mg once daily for 3 months are superior to the other 2 tested therapy regimen in this patient cohort."
01/01/2012 - "Dabigatran and rivaroxaban have also been shown to be effective in the treatment of acute venous thromboembolism. "
01/01/2011 - "Our study demonstrates the need for further randomised controlled clinical trials to be conducted to assess the safety and efficacy of rivaroxaban in clinical practice, focusing on the surgical complications as well as the potential prevention of venous thromboembolism."
01/01/2010 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in phase-II and phase-III trials involving over 24,000 patients. "
06/01/2008 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients. "
01/01/2005 - "The THRombin Inhibitor in VEnous thromboembolism (THRIVE) clinical trial programme has demonstrated that this agent is as effective as standard therapy for the acute treatment (THRIVE Treatment) and secondary prevention (THRIVE lll) of VTE events and is well tolerated when used for 6 months or over extended periods up to 1.5 years. "
03/15/2002 - "Low-molecular-weight and unfractionated heparins are frequently used to treat venous thromboembolism, but it is not known whether they are equally effective in inhibiting in vivo generation of thrombin. "
10/01/2015 - "In patients with documented venous thromboembolism, increased thrombin generation values are seen in those patients at greatest risk for recurrence. "
02/01/2014 - "Inherited anti-thrombin deficiency is an autosomal dominant disorder which is associated with increased risk for venous thromboembolism (VTE). "
02/01/2012 - "The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous thromboembolism using fixed doses without the need for adjustment according to laboratory results. "
|9.||Vitamin KFDA Link
01/01/2005 - "Clinical-based evidence demonstrates that long-term oral anticoagulant therapy with the vitamin K antagonists is highly effective for the secondary prevention of venous thromboembolism (VTE). "
12/01/2003 - "Oral anticoagulation with vitamin-K-antagonists is very effective in secondary prevention of venous thromboembolism. "
01/01/2002 - "Omitting a potentially-confounded study, a statistically non-significant reduction in the risk of recurrent venous thromboembolism favoring vitamin K antagonist treatment remained (OR 1.95; 95% CI [0.74, 5.19]). "
01/01/2000 - "This OR was mainly due to one possibly confounded study, and after omitting this study from the analysis a statistically non-significant reduction of the risk of recurrent symptomatic venous thromboembolism in favor of vitamin K antagonist treatment remained (OR 1.95; 95% CI [0.74, 5.19]). "
02/01/2015 - "We performed a meta-analysis of randomized controlled trials (RCTs) comparing DOACs with vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). "
01/01/2005 - "Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism."
10/01/2005 - "Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study."
03/01/2006 - "Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran."
08/01/2005 - "Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery."
07/01/2005 - "Ximelagatran has already been approved in Europe for prophylaxis of venous thromboembolism in patients undergoing hip or knee surgery. "
09/01/2010 - "Unicompartmental arthroplasty using less invasive surgical techniques, a rapid recovery protocol, and multimodal venous thromboembolism prevention is a safe and effective procedure associated with a low rate of morbidity."
12/01/2015 - "Contrast-enhanced Computed Tomography Screening Is Effective for Detecting Venous Thromboembolism not Prevented by Prophylaxis after Total Knee Arthroplasty."
03/01/2012 - "This study evaluated the incidence of a venous thromboembolism (VTE) after total knee arthroplasty (TKA) using multidetector row computed tomography-indirect venography (MDCT-indirect venography) and assessed the efficacy of anti-coagulation therapy. "
03/01/2013 - "The goal of this meta-analysis was to evaluate the efficacy of venous foot pumps in prevention of venous thromboembolism following joint arthroplasty. "
03/01/2015 - "Despite current guidelines recommendations about anticoagulant prophylaxis, many studies have shown an high venous thromboembolism (VTE) incidence in patients undergoing total hip and knee arthroplasty. "
|2.||Hip Replacement Arthroplasty (Total Hip Replacement)
01/01/2014 - "There is a lack of evidence from randomized controlled trials to make an informed choice of IPC device for preventing venous thromboembolism (VTE) following total hip replacement. "
01/01/2012 - "There is a lack of evidence from randomized controlled trials to make an informed choice of IPC device for preventing venous thromboembolism (VTE) following total hip replacement. "
09/15/2010 - "The purpose of this study was to examine potential patient-related risk factors for venous thromboembolism following total hip replacement in a nationwide follow-up study. "
03/01/2002 - "The phase II Pentathlon trial demonstrated significant dose-dependent reductions in the frequency of venous thromboembolism in total hip-replacement patients and the optimal dose was determined to be 2.5 mg s.c./24 h. "
06/08/1994 - "To clarify this issue, we performed a meta-analysis of the randomized trials of methods used to prevent venous thromboembolism following total hip replacement. "
|3.||Knee Replacement Arthroplasty (Total Knee Replacement)
01/01/2011 - "This study compared uF1+2 levels in patients with symptomatic and non-symptomatic venous thromboembolism (VTE) after total knee replacement (TKR) and in event-free sex- and age-matched controls. "
07/03/2001 - "The present study was performed to determine an efficacious and safe dose of rNAPc2 for prevention of venous thromboembolism after elective, unilateral total knee replacement. "
09/01/2015 - "Trimodal venous thromboembolism prophylaxis in total knee replacement: A quality improvement project for best care practices."
09/01/2012 - "Prophylaxis for venous thromboembolism after total knee replacement (TKR) is standard of care. "
01/01/2012 - "Patients undergoing major orthopaedic surgery (MOS), such as total hip (THR) or total knee replacement (TKR), are at high risk of developing venous thromboembolism (VTE). "
|4.||Vena Cava Filters (Inferior Vena Cava Filter)
09/01/2009 - "Permanent/retrievable vena cava filters are safe and effective devices for PE prophylaxis and for the management of venous thromboembolism by providing the option to be left in place."
09/01/2008 - "Recent trials have demonstrated the efficacy of short-term insertion of inferior vena cava filters in the treatment and prophylaxis of venous thromboembolism certain populations, especially those with a reversible contraindication to anticoagulation. "
12/01/2011 - "Inferior vena cava filter placement could be helpful for venous thromboembolism prophylaxis. "
11/01/2005 - "To evaluate the success, safety, and efficacy of the retrieval of the OptEase Permanent/Retrievable Vena Cava Filter (Cordis, Warren, NJ), when implanted for temporary protection against venous thromboembolism. "
09/13/2010 - "A population-based study of inferior vena cava filters in patients with acute venous thromboembolism."
|5.||Drug Therapy (Chemotherapy)
12/15/2005 - "Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study."
07/01/2015 - "Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis."
04/01/2015 - "Pharmacotherapy with oral Xa inhibitors for venous thromboembolism."
03/25/2015 - "To examine student engagement with, perception of, and performance resulting from blended learning for venous thromboembolism in a required cardiovascular pharmacotherapy course for second-year students. "
11/01/2014 - "A recent meta-analysis showed that the risk of chemotherapy-associated venous thromboembolism was increased by 1.67-fold when CDDP was included in the chemotherapy regimen. "